ABSTRACT

Introduction IBD includes a scope of digestive pathologies, the most well-known of which are UC and CD. Both UC and CD, when present in the colon, produce a comparable side effect profile which can incorporate looseness of the bowels, rectal dying, and weight loss. The Mesalazine is an anti-inflammatory agent structurally related to the salicylates and non-steroidal anti- inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease. Ellagic acid is a natural anti-oxidant phenol found in numerous fruits in particular abundant amount pomegranate. In pomegranates, there are several therapeutic compounds but Ellagic acid is the most active and abundant. Ellagic acid is also present in vegetables the anti-proliferative and anti-oxidant properties of Ellagic acid have prompted research into its potential health benefit. We aimed to investigation of Ellagic acid alone and its combination with Mesalazine on experimentally induced IBD in mice. Materials and Methods: Colitis severity and inflammation-associated damage can be assessed by examining stool consistency and bleeding, In the acute UC model, female Balb/C mice were treated with DSS (5%) for seven days while concomitantly receiving a combination of dietary supplement of ellagic acid (2%) and anti-inflammatory agent Mesalazine in the IBD model, Result: Ellagic acid combination with Mesalazine significantly improved changes in the length of the colon and inhibited the progression of the disease, reducing intestinal inflammation and decreasing histological scores in DSS-induced colitis in mice. Conclusion: The result shows that treatment with Ellagic Acid and Mesalazine individually is able to improve the inflammatory conditions by suppressing the various inflammatory mediators. Keywords: Inflammatory Bowel Disease, Ellagic acid, Mesalazine, DSS
Publication date: 01/05/2023

https://ijbpas.com/pdf/2023/May/MS_IJBPAS_2023_7131.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2023/12.5.7131